TripSitter Clinic Ltd (KETA) AI Stock Analysis

• Market Cap: C$532.65K
• Dividend Yield: N/A
• Average Volume (3M): 1.71K
• Price to Earnings (P/E): ―
• Beta (1Y): -13.46
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): >-0.01
• Shares Outstanding: 6,658,174
• 10 Day Avg. Volume: 150
• 30 Day Avg. Volume: 1,705
• PEG Ratio: 0.29
• Price to Book (P/B): -0.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: C$0.06 ▲(1.67% Upside)
• Action: Downgraded Date: 02/15/26
• Date: Action: Downgraded 02/15/26

The score is driven primarily by very weak financial performance (near-zero revenue, ongoing losses, negative equity, and continued cash burn), which outweighs any near-term technical oversold signals. Valuation is also unattractive/unclear due to negative earnings and no dividend support.

Positive Factors

Reduced cash burn

Free cash flow losses have materially narrowed versus the very large outflows in FY2022–FY2024. A smaller absolute cash burn improves runway and reduces near-term refinancing urgency, increasing the odds management can execute a restructuring or revenue restart over months.

Negative Factors

Revenue collapse

Revenue near zero eliminates operating scale and renders gross margins and unit economics non-informative. With minimal sales, fixed costs and selling efforts cannot be absorbed, making sustainable profitability dependent on a material and durable revenue reboot or significant restructuring.

TripSitter Clinic Ltd Business Overview & Revenue Model

Company Description

TripSitter Clinic Ltd. operates a consultative virtual clinic and tele-health platform that connects patients to a licensed physician who can evaluate for a prescribed treatment program of low-dose oral ketamine medication in the United States. It...

Read more

TripSitter Clinic Ltd. operates a consultative virtual clinic and tele-health platform that connects patients to a licensed physician who can evaluate for a prescribed treatment program of low-dose oral ketamine medication in the United States. It...

How the Company Makes Money

null...

TripSitter Clinic Ltd Financial Statement Overview

Breakdown	TTM	Apr 2024	Jan 2024	Jan 2023	Jan 2022	Jan 2021
Income Statement
Total Revenue	0.00	0.00	13.97K	488.30K	87.22K	0.00
Gross Profit	0.00	0.00	-4.70K	138.71K	-554.60K	0.00
EBITDA	-4.64K	-9.61K	-348.48K	-1.85M	-10.22M	-177.59K
Net Income	-4.64K	-9.61K	-304.86K	-1.87M	-26.11M	-179.33K
Balance Sheet
Total Assets	598.00	1.20K	2.83K	99.27K	1.46M	780.68K
Cash, Cash Equivalents and Short-Term Investments	598.00	1.20K	2.83K	54.85K	1.30M	772.39K
Total Debt	389.11K	339.62K	273.05K	133.50K	133.50K	17.88K
Total Liabilities	816.44K	748.57K	730.57K	548.82K	197.59K	93.36K
Stockholders Equity	-815.84K	-747.37K	-727.74K	-449.55K	1.26M	687.32K
Cash Flow
Free Cash Flow	-55.19K	-46.52K	-201.59K	-1.39M	-1.76M	-92.97K
Operating Cash Flow	-55.19K	-46.52K	-201.59K	-1.39M	-1.76M	-92.97K
Investing Cash Flow	0.00	0.00	0.00	0.00	2.30M	0.00
Financing Cash Flow	53.66K	54.91K	139.54K	136.43K	16.16K	865.37K

TripSitter Clinic Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VHI	68 Neutral	C$436.30M	90.72	2.75%	―	59.34%	-23.48%
CHS	53 Neutral	C$12.38M	-11.57	―	―	16.04%	-455.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AIDR	48 Neutral	C$50.98M	-2.31	-207.53%	―	―	7.04%
UDOC	42 Neutral	C$9.93M	-5.12	6239.15%	―	―	48.94%
KETA	38 Underperform	C$532.65K	-7.33	0.59%	―	―	―